TauRx Chairman Claude Wischik On Waging A Battle Against Alzheimer’s Disease His Way: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Claude Wischik has spent more than a decade working on a drug that would inhibit the aggregation of tau tangles in the brain, and says his work has put the Singapore-based company TauRx Pharmaceuticals Ltd. onto a path that could produce the world’s best-selling drug, surpassing Pfizer Inc.’s Lipitor (atorvastatin).
You may also be interested in...
The acquisition of a tau PET imaging portfolio from Siemens further expands Lilly’s Alzheimer’s program.
Luminex will develop a companion diagnostic for Merck’s BACE Inhibitor, MK-8931, that will test patients’ cerebrospinal fluid for the presence of two biomarkers that could indicate they are at risk of developing Alzheimer’s disease.
With the potential for a multi-billion-dollar blockbuster on its hands, Eli Lilly could conduct a confirmatory trial or even seek near-term approval of sola after pooled data revealed a hint of disease modifying potential in mildly affected Alzheimer’s patients, though the company also may be grasping at straws.